Abstract

Accumulation of evidence has indicated a close relationship between alternative splicing (AS) and gastric cancer (GC), whereas systematic analyses of the differentially expressed AS events (DEAS) between GC and normal tissues are lacking. RNA-Seq data and the corresponding clinical information were downloaded from TCGA GC cohort. The percent spliced-in (PSI) value calculated in the GC tissues and normal tissues was employed to quantify the DEAS. Further, survival-associated DEAS and DEAS signatures were identified by univariate and multivariate cox regression analyses. To evaluate the association between DEAS and patients’ clinical features, Kaplan-Meier analysis, receiver operator characteristic (ROC) curve, Cox proportional regression and nomograms incorporating the DEAS signatures were performed. DEAS and their splicing networks were finally analyzed by bioinformatics methods. In addition, we use the method of random grouping to divide the samples into the training group and the test group. The final results of the two groups are consistent. After strict filtering, a total of 44,935 AS events were identified, among which 11,141 DEAS were preliminarily screened from 5032 genes. A total of 454 DEAS was associated with OS, and 872 DEAS were associated with DFS. The final prognostic signatures were constructed from the survival-associated DEAS with an area under the receiver operating characteristic (ROC) curve (AUC) greater than 0.6. Only ES in ABI1 was simultaneously associated with OS and DFS. Finally, we identified the splicing correlation network between the prognostic splicing factors (SF) and DEAS in GC. Our study provided a systematic portrait of survival-associated DEAS in GC and uncovered splicing networks that are valuable in deciphering the underlying mechanisms of AS in GC.

Highlights

  • Gastric cancer (GC) is the fifth diagnosed cancer and the third leading cause of cancer-related death worldwide (Bray et al, 2018)

  • By using SpliceSeq on the RNA-Seq data of gastric cancer (GC) patients, we found a total of 44,935 alternative splicing (AS) events in 10,256 genes, including 17,274 exon skip (ES) in 2,273 genes, 198 mutually exclusive exons (ME) in 31 genes, 2,738 retained intron (RI) in 658 genes, 9,573 alternate promoter (AP) in 3,844 genes, 8,198 alternate terminator (AT)

  • Preliminary investigations revealed that the potential significance of AS perturbation was involved in the initiation and progression of cancer by generating different mRNA and protein isoforms with diverse functional properties (He et al, 2004; Kameyama et al, 2012)

Read more

Summary

Introduction

Gastric cancer (GC) is the fifth diagnosed cancer and the third leading cause of cancer-related death worldwide (Bray et al, 2018). The results obtained from the studies mentioned above identified GCrelated alterations in a number of oncogenes, such as KRAS (Till et al, 2017), c-MET (Bradley et al, 2017), and c-Myc (Khanna et al, 2009), and revealed the complicated relationship that govern GC malignant progression. These studies, with promising results, often showed diametrically opposite results. The reason for these kinds of results is that there are many transcripts and variants of these genes (Chen et al, 2018)

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.